Qual é o preço para IMV Inc. (IMV)

O preço para IMV Inc. (IMV) é $0.82959892

Qual é a capitalização de mercado para IMV Inc. (IMV)

A capitalização de mercado para IMV Inc. (IMV) é $4.16M

Histórico de Preços de IMV Inc. (IMV)

IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.

Ano	Desempenho
2023	-68.78%
2022	-80.40%
2021	-58.02%
2020	14.41%
2019	-48.63%
2018	2.19%
2017	210.21%
2016	-3.76%
2015	-10.27%
2014	42.27%
2013	23.64%
2012	0.00%

Ano

Desempenho

2023

-68.78%

2022

-80.40%

2021

-58.02%

2020

14.41%

2019

-48.63%

2018

2.19%

2017

210.21%

2016

-3.76%

2015

-10.27%

2014

42.27%

2013

23.64%

2012

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Empresa

Preço da ação

Variação 1a%

País